Biohaven Ltd.

Biohaven Ltd. is a biopharmaceutical company that develops and seeks to commercialize treatments in neuroscience, immunology, and oncology. The company was spun out of Biohaven Pharmaceutical Holding Company Ltd. in October 2022 and now operates as an independent public company listed on the NYSE under BHVN. Its current development strategy is centered on a smaller set of late-stage programs, including Kv7 ion channel modulation for epilepsy, MoDE/TRAP extracellular protein degradation for immunological diseases, and a myostatin-activin pathway program for neuromuscular and metabolic disorders. Biohaven does not yet generate product revenue and remains in a clinical-development and capital-allocation phase.

3.18

3.18

— Biohaven Ltd.
%
Neuroscience programs35% Drug candidates targeting neurological disorders, including epilepsy and other CNS indications.
Immunology programs35% MoDE and TRAP-based therapies designed to degrade disease-causing extracellular proteins in immune-mediated diseases.
Neuromuscular and metabolic programs20% Myostatin-activin pathway therapies aimed at muscle, metabolic, and obesity-related diseases.
Oncology programs10% Early- to mid-stage oncology research and development efforts within the broader pipeline.

Biohaven’s direct customers are not patients today but rather regulators, clinical investigators, and eventually...

  • Clinical development partnersprimary

    CROs, trial sites, and contract manufacturers that execute Biohaven’s outsourced R&D model and enable pipeline advancement.

  • Regulatory agenciesprimary

    The FDA and comparable agencies that determine whether product candidates can progress to approval and commercialization.

  • Future specialty prescriberssecondary

    Neurologists, immunologists, and other specialists who would prescribe approved therapies for targeted diseases.

  • Payers and health systemssecondary

    Commercial and government payers that would assess clinical value, pricing, and reimbursement for approved products.

Biohaven is legally organized in the British Virgin Islands, with its U.S. operating subsidiary based in New Haven,...

  • •Incorporated in the British Virgin Islands, with NYSE listing in the United States
  • •U.S. subsidiary in New Haven, Connecticut anchors operations
  • •Irish subsidiary supports development and tax structure
  • •R&D and clinical activity are primarily U.S.- and Ireland-linked
  • •No disclosed country revenue because the company has not yet generated product sales

Biohaven’s strategy is to concentrate resources on a smaller number of late-stage programs with the highest perceived...

01
Focus on three key clinical programsshort-term

Concentrating resources should improve execution probability and reduce dilution of capital across too many projects.

02
Advance programs through clinical proof-of-concept and regulatory milestonesmedium-term

Clinical and regulatory success is the main value driver because the company has no product revenue yet.

03
Maintain capital flexibility and optionalityshort-term

The company expects continued operating losses and may need additional funding or partnerships to support development and commercialization.

Biohaven faces the classic risks of a clinical-stage biopharmaceutical company: it has no product revenue, significant...

critical

Clinical development failure

Pipeline value depends on successful trial outcomes across late-stage programs.

Scope
Kv7, MoDE/TRAP, and myostatin-activin programs
Materiality
high
high

Need for additional capital

The company has no product sales and expects substantial future spending on trials and commercialization.

Scope
Pipeline funding and operating runway
Materiality
high
high

Regulatory approval risk

FDA or foreign agency delays or rejection would prevent commercialization and reduce asset value.

Scope
Marketing approval, orphan designation, and post-approval compliance
Materiality
high
high

Third-party manufacturing and trial execution risk

Outsourced development makes the company dependent on external vendors for timelines and quality.

Scope
CROs, contract manufacturers, supply chain
Materiality
medium
high

Intellectual property disputes

Patent challenges or loss of licensed rights could undermine exclusivity and future economics.

Scope
Pipeline patents and licensed IP
Materiality
medium
Accrued research and development expenses
Can shift operating expenses and net loss between periods
Deferred tax asset valuation allowance
Affects tax benefit recognition and reported equity
Fair value of Note Purchase Agreement
Can create non-cash gains or losses in earnings
Quarterly R&D volatility
Makes period-to-period comparisons less comparable

BIOVIE INC.

BIVI · Pharmaceutical Preparations

Xenon Pharmaceuticals Inc.

XENE · Pharmaceutical Preparations

BIO-PATH HOLDINGS, INC.

BPTH · Pharmaceutical Preparations

BIOLIFE SOLUTIONS INC

BLFS · Electromedical & Electrotherapeutic Apparatus

BIOGEN INC.

BIIB · Biological Products, (No Diagnostic Substances)

BioScience Health Innovations, Inc.

BHIC · Services-Computer Processing & Data Preparation

: 11/08/2026